Matthew Rabinowitz sold $16M of NTRA
EXECUTIVE CHAIRMAN at Natera, Inc.. 50,000 shares at an average of $327.97, traded Sep 11, 2026, filed Sep 11, 2026.
Score components
- +20RoleChair
- +25Trade size$16.4M at market
- 0Share of holdings soldSold 2.2% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001646382-26-000019, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -800 | $325.01 | $260k | 2,274,594 | 31 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -3,647 | $326.11 | $1.2M | 2,270,947 | 31 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -10,556 | $327.14 | $3.5M | 2,260,391 | 31 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -17,933 | $327.97 | $5.9M | 2,242,458 | 31 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -15,764 | $328.95 | $5.2M | 2,226,694 | 31 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -1,300 | $329.62 | $429k | 2,225,394 | 31 d ago |
Related signals
Other insiders at Natera, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $526k 1,273 shares | -1% | |
| 40Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $1.2M 3,000 shares | -3% | |
| 55Moderate | Natera, Inc. | Jonathan Sheena director, other | $7.0M 18,064 shares | -100% | |
| 35Weak | Natera, Inc. | Jonathan Sheena director, other | $3.2M 9,150 shares | -4% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $35M 102,000 shares | -5% | |
| 39Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $545k 1,698 shares | -2% | |
| 45Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $5.9M 18,160 shares | -14% | |
| 34Weak | Natera, Inc. | Jonathan Sheena director, other | $908k 4,570 shares | -2% | |
| 10Weak | Natera, Inc. | Rowan E Chapman director | $23k 122 shares | -2% | |
| 25Weak | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $38M 200,000 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.